Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Neurocrine Biosciences Inc (NBIX) vs Stryker Corporation (SYK) Price & Performance

Neurocrine Biosciences IncTrade
Stryker CorporationTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs Stryker Corporation — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Stryker Corporation trades at $319.04 (market cap $122.35B). The key difference: Stryker Corporation is far larger — about 7× Neurocrine Biosciences Inc's market cap, and Stryker Corporation pays a 1% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

NBIXSYK
Market Cap
$17.40B$122.35B
Sector
HealthTechnology
52-Week High
$180.55$403.53
52-Week Low
$123.10$282.58
Enterprise Value
$16.49B$134.10B
Dividend Yield
1%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK